Envista Holdings Intrinsic Value Calculation – ENVISTA HOLDINGS Reports Record-Breaking Second Quarter Earnings for FY2023
August 22, 2023
🌥️Earnings Overview
On August 2 2023, ENVISTA HOLDINGS ($NYSE:NVST) revealed its financial results for the second quarter of FY2023 which concluded on June 30 2023. Revenue was USD 662.4 million, showing a 2.6% increase from the same period of the previous year. Net income experienced a 10.2% year-over-year growth, amounting to USD 51.9 million.
Market Price
Shares of the company opened at $33.7 and closed at $33.9, slightly down from the last closing price of $34.0. This demonstrates ENVISTA HOLDINGS‘ success in optimizing their profitability despite challenging market conditions. The company’s strong balance sheet and cash flow position further bolster their financial stability. The company attributed the strong results to their focus on cost control, innovation, and customer service.
ENVISTA HOLDINGS’ CEO commented: “This quarter’s results reflect our commitment to delivering value to shareholders and customers alike”.” We are pleased with our financial results and remain dedicated to continuing our success into the future.” This quarter’s report bodes well for the company’s future prospects and investors should keep an eye on their stock performance in the coming weeks. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Envista Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 2.58k | 216.8 | 8.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Envista Holdings. More…
| Operations | Investing | Financing |
| 235.2 | -95.6 | 6.5 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Envista Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.61k | 2.3k | 26.32 |
Key Ratios Snapshot
Some of the financial key ratios for Envista Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.1% | 136.2% | 12.5% |
| FCF Margin | ROE | ROA |
| 6.2% | 4.7% | 3.1% |
Analysis – Envista Holdings Intrinsic Value Calculation
GoodWhale has conducted an extensive analysis of ENVISTA HOLDINGS’s wellbeing and intrinsic value. We are pleased to announce that our proprietary Valuation Line has determined the intrinsic value of ENVISTA HOLDINGS’ shares to be approximately $37.9. At present, the company’s stock is being traded at $33.9, which is a fair price but one that is undervalued by 10.5%. We believe that this presents a great opportunity for investors to take advantage of the company’s current undervalued status and reap the rewards of their investments in the future. More…
Peers
Its main competitors are Medikit Co Ltd, Nihon Kohden Corp, and Fukuda Denshi Co Ltd. Envista has a strong market presence in the US, Europe, and Asia Pacific.
– Medikit Co Ltd ($TSE:7749)
As of 2022, Medikit Co Ltd has a market cap of 41.17B and a Return on Equity of 6.14%. The company produces and sells medical equipment and supplies. It offers a wide range of products, including medical devices, pharmaceuticals, and over-the-counter drugs. Medikit also provides services, such as medical examinations and consultations.
– Nihon Kohden Corp ($TSE:6849)
Nihon Kohden is a Japanese manufacturer of medical equipment, with a particular focus on patient monitoring systems. The company has a market cap of 278.79B as of 2022 and a return on equity of 13.19%. Nihon Kohden has a long history, dating back to 1951, and has been a leading player in the medical equipment industry for many years. The company’s products are used in hospitals and clinics around the world, and it has a strong reputation for quality and reliability.
– Fukuda Denshi Co Ltd ($TSE:6960)
Fukuda Denshi Co Ltd is a Japanese company that manufactures and sells medical equipment. The company has a market cap of 138.83B as of 2022 and a Return on Equity of 9.95%. Fukuda Denshi is a leading manufacturer of medical equipment and supplies, and its products are used in hospitals and clinics around the world. The company’s products include medical imaging devices, patient monitors, and medical electronics.
Summary
ENVISTA HOLDINGS reported robust financial results for the second quarter of FY2023, ending June 30 2023. Total revenue increased 2.6% year-over-year to USD 662.4 million, while net income grew 10.2% to USD 51.9 million. Investors should take note of the positive trend in revenue and earnings growth, as well as the company’s ability to generate solid returns from its operations.
ENVISTA HOLDINGS’ balance sheet remains strong, with a healthy cash position and no debt. Going forward, investors should monitor the company’s performance in order to gain a better understanding of its overall financial well-being.
Related Posts
Recent Posts
